Relebactam

Research use only, not for human use.

Relebactam (MK-7655) is a novel β-lactamase inhibitor that inhibited both class A and C β-lactamases in vitro.

Relebactam (MK-7655) is a novel β-lactamase inhibitor that inhibited both class A and C β-lactamases in vitro; effectively restored imipenem's activity against imipenem-resistant Pseudomonas and Klebsiella strains at clinically achievable concentrations; reduces imipenem MICs for Enterobacteriaceae with KPC carbapenemases from 16-64 mg/L to 0.12-1 mg/L at a concentration of 4 mg/L.Bacterial Infection Phase 3 Clinical(In Vitro):Relebactam combine with Imipenem demonstrates activity against KPC-producing Enterobacteriaceae and multidrug-resistant P. aeruginosa.Relebactam shows limited inhibition of Class D-producing bacteria and has antipseudomonal activity.

——

——

MK-7655

GPCR/G Protein

Antibacterial

diazabicyclooctane

Infection

Bacterial Infection

1174018-99-5

348.3754

C12H20N4O6S

>98% (HPLC)

10 mM in DMSO

O=S(O)(ON1[C@]2([H])CC[C@@H](C(NC3CCNCC3)=O)[N@@](C2)C1=O)=O

Sulfuric acid, mono[(1R,2S,5R)-7-oxo-2-[(4-piperidinylamino)carbonyl]-1,6-diazabicyclo[3.2.1]oct-6-yl] ester

(-20℃)

With Ice Pack

≥ 2 years